Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 21, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,600,000 Ordinary shares
- Purchase Price: 1,302.35 pence per share
- Treasury Shares Held: 319,639,158 (representing 5.61% of total voting rights)
- Shares in Issue: 5,701,118,036 (excluding Treasury shares)
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 1,600,000 shares on June 21, 2007. These shares are held in Treasury. The filing does not provide comparative financial data to assess changes in operating performance versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory disclosures regarding the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,701,118,036) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (319,639,158) and its impact on total voting rights (5.61%).
- Review the Annual General Meeting minutes from May 23, 2007, to understand the full scope of the share repurchase authority.